NCT03336333 2026-03-09SEQUOIABeOne MedicinesPhase 3 Active not recruiting590 enrolled 12 charts 1 FDA
NCT06073821 2026-03-04Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)BeOne MedicinesPhase 3 Active not recruiting652 enrolled
NCT04170283 2025-10-21Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Participants With B-cell MalignanciesBeOne MedicinesPhase 3 Active not recruiting955 enrolled